Electromed Inc. Common Stock (ELMD)

FairStock Score: 73/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Electromed as a small, focused medical-device maker. Its SmartVest system treats compromised pulmonary function, and the filed numbers show a real business: in fiscal 2026, the year ended 2026-06-30, revenue was $73.8 million, net income $11.3 million, and diluted EPS $1.30; in fiscal 2025, the year ended 2025-06-30, revenue was $64.0 million, net income $7.5 million, and diluted EPS $0.85. That is roughly 15% revenue growth and 51% net-income growth. Fiscal 2024, the year ended 2024-06-30, had revenue $54.7 million, net income $5.2 million, and diluted EPS $0.58, so the trajectory is upward. The balance sheet looks conservative: FairStock shows no debt to equity, at 0.00, ROE of 23.26%, ROCE of 14.45%, and an Altman Z-Score of 13.21. Free cash flow is $8.4 million trailing twelve months, a 3.6% FCF yield. But Graham would not call it cheap. At the 2026-10-13 close of $27.68, FairStock's P/E is 21.29, P/B is 4.29, and the Graham Number is $13.74, leaving a negative margin of safety of about 101%. FairStock's Piotroski F-Score is only 3/9, a caution flag. The Lynch category is FAST GROWER, with 36.8% annual profit growth and 15.6% revenue growth over five years, and the PEG ratio is 0.36. So I see a growing, financially sturdy niche business, but the price already reflects much of the growth and offers little asset-based protection.

In plain English: Electromed makes a device called SmartVest that helps people with lung conditions clear their airways. The business is growing sales and profits, has no debt, and produces cash. The shares look priced for continued growth rather than bargain cheap, and strict old-school value measures suggest they are not on sale.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2026 10-Q (period ended 2025-12-31) · fiscal Q1 2026 10-Q (period ended 2025-09-30) · fiscal Q3 2025 10-Q (period ended 2025-03-31) · FY2026 10-K (period ended 2026-06-30) · FY2025 10-K (period ended 2025-06-30) · FY2024 10-K (period ended 2024-06-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer